| Name | Title | Contact Details |
|---|
The PAISBOA Health Benefit Trust (HBT) is a consortium of independent schools, colleges, and universities within the state of Pennsylvania. The sole focus of the HBT is to provide high-quality health plans at affordable rates. Members enjoy savings, stability, and innovative programs through scale and collaboration. The PAISBOA HBT is a self-funded entity, organized as a Multiple Employer Welfare Association (MEWA). While the HBT was established by and exists for the benefit of its member institutions, it is governed by a dedicated Board of Trustees who are elected by the members to ensure that the needs of all of the enrolled participants are represented.
Meyer Laboratory, also known as Meyer Lab, is a U.S.-based chemical manufacturer that specializes in industrial and institutional cleaning chemicals and application systems. Founded in 1978 by Russ Meyer, the company has established itself as a leader in the North American market for industrial cleaning solutions. Meyer Lab focuses on delivering customized cleaning programs that meet the specific needs of its customers. The company offers a wide range of services, including tailored cleaning programs that aim to reduce chemical and labor costs, maintenance services for cleaning equipment, and training for effective product use. Meyer Lab also provides inventory management assistance and supplies advanced dispensing systems to enhance safety and efficiency in chemical use. Their product portfolio features various hard surface cleaning chemicals, such as degreasers, disinfectants, sanitizers, and surfactant blends, which are designed for multiple industrial and manufacturing markets. Meyer Lab is committed to supporting environmental initiatives by providing effective and efficient cleaning solutions.
The Federal Community Defender Office for the Eastern District of Pennsylvania, an office within the Defender Association of Philadelphia, is the designated Federal Community Defender Organization for the United States District Court for the Eastern District of Pennsylvania. Since its creation in 1972, the Federal Community Defender Office has been funded to render Defender Services to individuals who are unable to afford counsel and who are under investigation for, or charged with, violations of the laws of the United States, and to federal death-sentenced prisoners in Pennsylvania and elsewhere, when appointed. Upon appointment by the District Court or the Third Circuit Court of Appeals, the office provides representation for individuals who have been subpoenaed to appear before investigating Grand Juries, who are named defendants in criminal complaints, or who have been indicted by a Grand Jury. The representation, once undertaken, remains throughout the pendency of the proceedings, up to and including applications for relief to the Supreme Court of the United States. In addition, upon appointment, the office represents state and federal prisoners who are seeking relief by way of Habeas Corpus application in both the District Court and the Court of Appeals.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.